[go: up one dir, main page]

CL2011000744A1 - Uso de una fromulacion farmaceutica de mesalamina granulada util en la remision de la colitis ulertiva en un sujetoi durante un periodo de la menos 6 meses - Google Patents

Uso de una fromulacion farmaceutica de mesalamina granulada util en la remision de la colitis ulertiva en un sujetoi durante un periodo de la menos 6 meses

Info

Publication number
CL2011000744A1
CL2011000744A1 CL2011000744A CL2011000744A CL2011000744A1 CL 2011000744 A1 CL2011000744 A1 CL 2011000744A1 CL 2011000744 A CL2011000744 A CL 2011000744A CL 2011000744 A CL2011000744 A CL 2011000744A CL 2011000744 A1 CL2011000744 A1 CL 2011000744A1
Authority
CL
Chile
Prior art keywords
useful
ulertive
remission
colitis
months
Prior art date
Application number
CL2011000744A
Other languages
English (en)
Inventor
William Forbes
Original Assignee
Dr Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Falk Pharma Gmbh filed Critical Dr Falk Pharma Gmbh
Publication of CL2011000744A1 publication Critical patent/CL2011000744A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulación farmacéutica que comprende mesalamina granulada, útil en el tratamiento de un trastorno gastrointestinal tal como enfermedad de colon irritable y trastornos de movilidad.
CL2011000744A 2008-10-03 2011-04-04 Uso de una fromulacion farmaceutica de mesalamina granulada util en la remision de la colitis ulertiva en un sujetoi durante un periodo de la menos 6 meses CL2011000744A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10280708P 2008-10-03 2008-10-03
US10970808P 2008-10-30 2008-10-30

Publications (1)

Publication Number Publication Date
CL2011000744A1 true CL2011000744A1 (es) 2011-09-16

Family

ID=42073898

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000744A CL2011000744A1 (es) 2008-10-03 2011-04-04 Uso de una fromulacion farmaceutica de mesalamina granulada util en la remision de la colitis ulertiva en un sujetoi durante un periodo de la menos 6 meses

Country Status (13)

Country Link
US (1) US8865688B2 (es)
EP (1) EP2334178A4 (es)
JP (1) JP5740306B2 (es)
CN (1) CN102238868A (es)
AU (1) AU2009298139B2 (es)
CA (1) CA2739465C (es)
CL (1) CL2011000744A1 (es)
EA (1) EA022886B1 (es)
IL (1) IL212057A (es)
MX (1) MX2011003595A (es)
NZ (1) NZ592049A (es)
WO (2) WO2010040021A1 (es)
ZA (1) ZA201102442B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102319218B (zh) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
MX2014013719A (es) * 2012-05-19 2015-02-10 Falk Pharma Gmbh Composiciones y metodos para el tratamiento del sindrome del intestino irritable con 5-aminosalicilato.
MX370795B (es) 2012-06-15 2020-01-08 Conaris Res Institute Ag Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal.
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
CN105307644B (zh) 2013-03-15 2019-07-23 沃纳奇尔科特有限责任公司 用于减少递送变化性的具有多种剂量单元的美沙拉嗪药物组合物
CN104706582A (zh) * 2013-12-12 2015-06-17 四川健能制药有限公司 含有美沙拉秦的药物组合物
EP3079675B1 (en) 2013-12-13 2020-02-12 CONARIS research institute AG A pharmaceutical composition containing nicotinic acid and/or nicotinamide for use in beneficially influencing blood lipid levels by modifying the intestinal microbiota
US10758552B2 (en) 2013-12-13 2020-09-01 Conaris Research Institute Ag Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
EP3421538B1 (en) 2017-06-30 2021-03-17 Borealis AG Polyolefin composition with improved surface appearance

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449553A (en) * 1891-03-31 Building-front column
US1800002A (en) 1923-07-13 1931-04-07 Gen Electric System of distribution
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2897121A (en) * 1957-06-04 1959-07-28 Upjohn Co Pharmaceutical composition
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3938515A (en) * 1971-12-20 1976-02-17 Alza Corporation Novel drug permeable wall
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4668517A (en) * 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
JPS6261916A (ja) 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) * 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
DE9015551U1 (de) 1990-11-14 1992-03-12 Röhm GmbH, 6100 Darmstadt Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccarid
WO1992016214A1 (en) 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
WO1993007859A1 (en) 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
FR2692484B1 (fr) 1992-06-22 1995-06-30 Gouchet Franck Nouvelle forme galenique de 4-asa a liberation controlee.
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
FI98343C (fi) 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
AU702934B2 (en) 1995-12-21 1999-03-11 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6227412B1 (en) * 2000-03-03 2001-05-08 Saint-Gobain Calmar Inc. Dip tube filter for manually actuated dispenser
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20070243184A1 (en) * 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
PT2099446E (pt) * 2006-11-17 2013-02-13 Shire Dev Inc Método de tratamento de doença inflamatória intestinal

Also Published As

Publication number Publication date
EP2334178A1 (en) 2011-06-22
IL212057A0 (en) 2011-06-30
MX2011003595A (es) 2011-07-28
US8865688B2 (en) 2014-10-21
WO2010040021A1 (en) 2010-04-08
JP5740306B2 (ja) 2015-06-24
NZ592049A (en) 2012-11-30
CN102238868A (zh) 2011-11-09
WO2010040113A1 (en) 2010-04-08
US20100086588A1 (en) 2010-04-08
IL212057A (en) 2016-12-29
CA2739465C (en) 2017-01-31
AU2009298139B2 (en) 2015-02-19
JP2012504658A (ja) 2012-02-23
EA201100565A1 (ru) 2011-10-31
CA2739465A1 (en) 2010-04-08
ZA201102442B (en) 2011-11-30
EP2334178A4 (en) 2012-04-11
EA022886B1 (ru) 2016-03-31
AU2009298139A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
CL2011000744A1 (es) Uso de una fromulacion farmaceutica de mesalamina granulada util en la remision de la colitis ulertiva en un sujetoi durante un periodo de la menos 6 meses
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
EA201000784A1 (ru) Антагонисты пути hedgehog и их терапевтические применения
CL2008001303A1 (es) Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2014002518A1 (es) Compuestos derivados heterociclicos nitrogenados, inhibidores de la bace-1 o de la bace-2; composicion farmaceutica que los comprende; combinacion farmaceutica; su uso en el tratamiento o prevencion de la enfermedad de alzheimer o un deterioro cognitivo leve.
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
EP2045251A4 (en) UBC13-EUV INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
EP2246052A4 (en) RASCH IN THE MOUTH DAMAGING TABLET WITH IMIDAFENACIN
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
CL2014000458A1 (es) Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades.
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
CL2008000091A1 (es) Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria.